{
  "docId": "019de077-72f9-7549-be02-1cb8598bb783",
  "docSlug": "e2ad68eb257d4e7a3f142ed0c8be9c7f",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 36,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes chemical structure of the benzoxaborole molecule.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-72f9-7549-be02-1cb8598bb783/26",
  "deckHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783",
  "deckJsonHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783.json",
  "deckAnchorHref": "/decks/019de077-72f9-7549-be02-1cb8598bb783#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.505,
        "y": 0.255
      },
      "kind": "image",
      "text": "Chemical structure of benzoxaborole",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a295edd0-c557-4622-a262-949b11d8d31e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.02,
        "y": 0.66
      },
      "kind": "list",
      "text": "Kills both actively dividing and dormant intracellular T. cruzi faster than benznidazole. Cures T. cruzi infection in mouse models.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ee18e81-3b4c-4cea-bab7-70dbee047771",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.02,
        "y": 0.235
      },
      "kind": "list",
      "text": "Novel target (CPSF3) is essential part of complex involved in RNA processing. Chemical class with 2 FDA-approved drugs (crisaborole and tavaborole). Target proof-of-concept through related benzoxaborole: acoziborole, human African trypanosomiasis drug candidate with 95% cure rate in Ph 2/3 study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1e5cd3f-d46e-46d8-91b8-af478a25cc5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.02,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "In vitro potency against a spectrum of genetically diverse strains of T. cruzi",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bd5ab6d-0335-4b51-bdd2-2a266e5ac454",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.02,
        "y": 0.185
      },
      "kind": "paragraph",
      "text": "Oral, small molecule benzoxaborole",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87dd0f5e-50e6-4307-af40-2b272ff774f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.22,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "AN2-502998 is formerly known as AN15368. 1. Padilla, A.M., et al. Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates. Nat Microbiol 7, 1536–1546 (2022). 2. Betu Kumeso VK, et al. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial. Lancet Infect Dis. 2023 Apr;23(4):463-470..",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "335e7ada-4f9a-4cf1-8a70-22afc9e5594b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "AN2-502998: Late Preclinical Drug Candidate with Curative Potential for Chronic Chagas Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1246195-a0e9-4660-8e84-6fb1ff30f5b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "6b32e1f2-f1ce-4b94-8adf-54b2ac5adf93",
      "evidence": "Novel target (CPSF3) is essential part of complex involved in RNA processing.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}